GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maravai LifeSciences Holdings Inc (NAS:MRVI) » Definitions » Piotroski F-Score

Maravai LifeSciences Holdings (Maravai LifeSciences Holdings) Piotroski F-Score : 4 (As of May. 04, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Maravai LifeSciences Holdings Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Maravai LifeSciences Holdings has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Maravai LifeSciences Holdings's Piotroski F-Score or its related term are showing as below:

MRVI' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 5   Max: 8
Current: 4

During the past 6 years, the highest Piotroski F-Score of Maravai LifeSciences Holdings was 8. The lowest was 4. And the median was 5.


Maravai LifeSciences Holdings Piotroski F-Score Historical Data

The historical data trend for Maravai LifeSciences Holdings's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maravai LifeSciences Holdings Piotroski F-Score Chart

Maravai LifeSciences Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial N/A N/A 8.00 5.00 4.00

Maravai LifeSciences Holdings Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 6.00 4.00 4.00

Competitive Comparison of Maravai LifeSciences Holdings's Piotroski F-Score

For the Biotechnology subindustry, Maravai LifeSciences Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maravai LifeSciences Holdings's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Maravai LifeSciences Holdings's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -0.067 + -6.541 + -6.462 + -105.959 = $-119.0 Mil.
Cash Flow from Operations was 85.074 + 19.194 + 14.166 + 7.79 = $126.2 Mil.
Revenue was 79.025 + 68.914 + 66.865 + 74.141 = $288.9 Mil.
Gross Profit was 45.349 + 25.641 + 30.179 + 39.033 = $140.2 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(2282.315 + 2315.388 + 2264.437 + 2267.553 + 1487.45) / 5 = $2123.4286 Mil.
Total Assets at the begining of this year (Dec22) was $2,282.3 Mil.
Long-Term Debt & Capital Lease Obligation was $598.1 Mil.
Total Current Assets was $699.9 Mil.
Total Current Liabilities was $87.5 Mil.
Net Income was 66.862 + 71.24 + 44.469 + 37.634 = $220.2 Mil.

Revenue was 244.293 + 242.732 + 191.263 + 204.713 = $883.0 Mil.
Gross Profit was 204.261 + 205.236 + 153.087 + 151.46 = $714.0 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(1918.276 + 2043.23 + 2171.799 + 2248.899 + 2282.315) / 5 = $2132.9038 Mil.
Total Assets at the begining of last year (Dec21) was $1,918.3 Mil.
Long-Term Debt & Capital Lease Obligation was $573.6 Mil.
Total Current Assets was $847.9 Mil.
Total Current Liabilities was $110.1 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Maravai LifeSciences Holdings's current Net Income (TTM) was -119.0. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Maravai LifeSciences Holdings's current Cash Flow from Operations (TTM) was 126.2. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-119.029/2282.315
=-0.05215275

ROA (Last Year)=Net Income/Total Assets (Dec21)
=220.205/1918.276
=0.11479318

Maravai LifeSciences Holdings's return on assets of this year was -0.05215275. Maravai LifeSciences Holdings's return on assets of last year was 0.11479318. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Maravai LifeSciences Holdings's current Net Income (TTM) was -119.0. Maravai LifeSciences Holdings's current Cash Flow from Operations (TTM) was 126.2. ==> 126.2 > -119.0 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=598.114/2123.4286
=0.2816737

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=573.553/2132.9038
=0.26890711

Maravai LifeSciences Holdings's gearing of this year was 0.2816737. Maravai LifeSciences Holdings's gearing of last year was 0.26890711. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=699.912/87.468
=8.0019207

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=847.902/110.144
=7.69812246

Maravai LifeSciences Holdings's current ratio of this year was 8.0019207. Maravai LifeSciences Holdings's current ratio of last year was 7.69812246. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Maravai LifeSciences Holdings's number of shares in issue this year was 132.141. Maravai LifeSciences Holdings's number of shares in issue last year was 255.323. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=140.202/288.945
=0.48522037

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=714.044/883.001
=0.80865594

Maravai LifeSciences Holdings's gross margin of this year was 0.48522037. Maravai LifeSciences Holdings's gross margin of last year was 0.80865594. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=288.945/2282.315
=0.12660172

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=883.001/1918.276
=0.46030967

Maravai LifeSciences Holdings's asset turnover of this year was 0.12660172. Maravai LifeSciences Holdings's asset turnover of last year was 0.46030967. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+0+1+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Maravai LifeSciences Holdings has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Maravai LifeSciences Holdings  (NAS:MRVI) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Maravai LifeSciences Holdings Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Maravai LifeSciences Holdings's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Maravai LifeSciences Holdings (Maravai LifeSciences Holdings) Business Description

Traded in Other Exchanges
Address
10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Executives
John A Deford director C R BARD INC, 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Rebecca Buzzeo officer: See Remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Andrew Burch officer: See Remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Martin William E. Iii officer: See remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Peter Michael Leddy officer: See Remarks 1620 FARADAY AVE, CARLSBAD CA 92008
Carl Hull director, officer: Chief Executive Officer 300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Gregory T Lucier director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kurt Oreshack officer: General Counsel 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Murali Prahalad director 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Lisa Sellers officer: See Remarks 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Susannah Gray director 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Robert B Hance director 300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Jessica Hopfield director C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Brian Neel officer: See Remarks 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Christine Dolan officer: See Remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121